Did the FDA request prospective human clinical data for your 510(k) submission? If so, it’s time to read up on regulatory requirements for quality assurance in human clinical studies. Failure to understand these requirements could lead to the FDA rejecting your clinical results, serious compliance actions, and a substantial waste of time and resources.
This white paper provides insight into these requirements and breaks down the key elements of an effective, compliant clinical study. We’ll answer your biggest questions about quality assurance measures for one of the most significant (and expensive) endeavors you can undertake on the road to FDA clearance.
What you will learn in this 5-page white paper:
Get answers to all of these questions and more in this white paper.
Robert Seiple, RAC (US): is Senior Regulatory Consultant at Emergo. He has over 35 years of experience with quality assurance and regulatory affairs in regulated industries, including medical devices, pharmaceuticals, and clinical research. His areas of expertise include 510(k) submissions, CE Marking, quality system implementation, training, and auditing.
自2018年起,美国食品和药物管理局(U.S. Food and Drug Administration,FDA)开始试行以电子化方式来帮助行业提供完整的510(k)上市前通知。2022年,为推进以电子格式提供510(k)递交文件的过渡,美国FDA正式发布关于使用电子递交模板和资源的最终指导文
阅读更多要在欧盟合法销售体外诊断器械(IVD),您需要拥有证明其符合IVD法规的CE标识。CE标志表明合法制造商已经评估了器械,并且器械符合体外诊断器械指令98/79/EC(IVDD)的基本要求或体外诊断器械法规2017/746(IVDR)的一般安全和性能要求。合法制造商将验证它的器械是否符合所有相关
阅读更多